

## EAHAD 2023 Novo Nordisk Symposium Agenda

# The Evolving Treatment Landscape in Haemophilia: Aiming for Optimal Outcomes for Patients

- This promotional symposium is organised and funded by Novo Nordisk and will be live streamed on the EAHAD platform
- Intended for healthcare professionals with an interest and expertise in haemophilia
- GB Prescribing Information and adverse event reporting will be available at this meeting.

[Click here for Esperoct® ▼ \(turoctocog alfa pegol\) GB Prescribing Information](#)

[Click here for Refixia® ▼ \(nonacog beta pegol\) GB Prescribing Information](#)

## Speakers

08 February 2023  
13:45 to 15:00 BST  
Room: Charter 1, 2, 3

13.45 - 13.50

### Welcome and introduction

Johnny Mahlangu, South Africa

13.50 - 14.10

### Treatment individualisation in haemophilia A

Johnny Mahlangu, South Africa

14.10 - 14.25

### The role of factor VIII in the current treatment landscape: Real-world data on patient experience

Hermann Eichler, Germany

14.25 - 14.45

### What does more ambitious prophylaxis mean for your patients with haemophilia B?

Kingsley Hampton, UK

14.45 - 15.00

### Panel discussion & Meeting closure

All



Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes

Registration conditions for Esperoct® and Refixia® may vary internationally. Always refer to the Summary of Product Characteristics (product label), as approved by regulatory authorities in your country